Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.

Paresh Dandona Chantal MathieuMoshe PhillipLars HansenDiethelm TschöpeFredrik ThorénJohn XuAnna Maria Langkildenull null

Published in: Diabetes care (2018)

Over 52 weeks, dapagliflozin led to improvements in glycemic control and weight loss in patients with type 1 diabetes, while increasing the risk of DKA.

Keyphrases

glycemic control
type diabetes
weight loss
blood glucose
bariatric surgery
roux en y gastric bypass
insulin resistance
gastric bypass
clinical trial
adipose tissue
gestational age
study protocol
weight gain